CA2464561A1 - Methods of treatment using a gastric retained losartan dosage - Google Patents

Methods of treatment using a gastric retained losartan dosage Download PDF

Info

Publication number
CA2464561A1
CA2464561A1 CA002464561A CA2464561A CA2464561A1 CA 2464561 A1 CA2464561 A1 CA 2464561A1 CA 002464561 A CA002464561 A CA 002464561A CA 2464561 A CA2464561 A CA 2464561A CA 2464561 A1 CA2464561 A1 CA 2464561A1
Authority
CA
Canada
Prior art keywords
dosage form
losartan
retained
administered
stomach
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002464561A
Other languages
English (en)
French (fr)
Inventor
John Devane
K. Iain Cumming
Sui Yuen Eddie Hou
Gloria M. Gusler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Assertio Holdings Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2464561A1 publication Critical patent/CA2464561A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002464561A 2001-10-25 2002-10-25 Methods of treatment using a gastric retained losartan dosage Abandoned CA2464561A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33524701P 2001-10-25 2001-10-25
US60/335,247 2001-10-25
PCT/IB2002/005438 WO2003035039A1 (en) 2001-10-25 2002-10-25 Methods of treatment using a gastric retained losartan dosage

Publications (1)

Publication Number Publication Date
CA2464561A1 true CA2464561A1 (en) 2003-05-01

Family

ID=23310913

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002464561A Abandoned CA2464561A1 (en) 2001-10-25 2002-10-25 Methods of treatment using a gastric retained losartan dosage

Country Status (5)

Country Link
US (1) US7413751B2 (enExample)
EP (1) EP1438027A1 (enExample)
JP (1) JP2005508358A (enExample)
CA (1) CA2464561A1 (enExample)
WO (1) WO2003035039A1 (enExample)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030152622A1 (en) * 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
US20030091630A1 (en) * 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
EP1492511B3 (fr) 2002-04-09 2012-05-02 Flamel Technologies Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s)
MXPA05007381A (es) 2003-01-13 2006-02-10 Dynogen Pharmaceuticals Inc Metodo para el tratamiento de transtornos funcionales del intestino.
ATE487478T1 (de) * 2003-01-30 2010-11-15 Lek Pharmaceuticals Herstellung eines neuen pharmazeutisch geeigneten losartan-salzes und von seinen formen mittels neuer reinigungs- und isolationsverfahren
KR20120058618A (ko) * 2003-01-31 2012-06-07 다이이찌 산쿄 가부시키가이샤 동맥 경화 및 고혈압증의 예방 및 치료를 위한 의약
WO2005079752A2 (en) * 2004-02-11 2005-09-01 Rubicon Research Private Limited Controlled release pharmaceutical compositions with improved bioavailability
US7838552B2 (en) * 2004-06-04 2010-11-23 Forest Laboratories Holdings Limited Compositions comprising nebivolol
JPWO2006046528A1 (ja) * 2004-10-29 2008-05-22 興和株式会社 糸球体疾患治療剤
FR2882260A1 (fr) * 2005-02-21 2006-08-25 Flamel Technologies Sa Forme pharmaceutique orale multimicroparticulaire a liberation modifiee d'antagonistes des recepteurs de l'angiotensine ii
FR2884145A1 (fr) * 2005-04-06 2006-10-13 Flamel Technologies Sa Forme pharmaceutique orale de losartan
EP1850835A1 (fr) * 2005-02-21 2007-11-07 Flamel Technologies Forme pharmaceutique orale de losartan
CA2613417C (en) * 2005-06-27 2011-11-29 Daiichi Sankyo Company, Limited Pharmaceutical preparation containing an angiotensin ii receptor antagonist and a calcium channel blocker
DE102005031577A1 (de) * 2005-07-06 2007-01-11 Bayer Healthcare Ag Pharmazeutische Darreichungsformen enthaltend eine Wirkstoffkombination von Nifedipin und/oder Nisoldipin und einem Angiotensin-II Antagonisten
ATE548035T1 (de) 2005-07-11 2012-03-15 Cortria Corp Formulierungen zur behandlung von lipoprotein- anormalitäten mit einem statin- und einem methylnicotinamid-derivat
TWI399223B (zh) * 2006-09-15 2013-06-21 Daiichi Sankyo Co Ltd 奧美沙坦酯及氨氯地平之固體劑型
KR100888131B1 (ko) * 2006-10-10 2009-03-11 한올제약주식회사 시간차 투약 원리를 이용한 심혈관계 질환 치료용 복합제제
WO2009084040A1 (en) * 2007-12-28 2009-07-09 Rubicon Research Private Limited Once a day formulation of angiotensin receptor blockers
WO2009114648A1 (en) 2008-03-11 2009-09-17 Depomed Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
US8372432B2 (en) 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
KR101209319B1 (ko) * 2008-04-29 2012-12-06 한올바이오파마주식회사 안지오텐신-ⅱ-수용체 차단제를 포함하는 약제학적 제제
UY32126A (es) * 2008-09-25 2010-04-30 Takeda Pharmaceutical Composición farmacéutica sólida
DE102008059206A1 (de) 2008-11-27 2010-06-10 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum
CN109394689A (zh) 2009-05-05 2019-03-01 德州大学系统董事会 挥发性麻醉剂的新型制剂及其用于减轻炎症的使用方法
US8597681B2 (en) 2009-12-22 2013-12-03 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
EP2392318A1 (en) 2010-05-21 2011-12-07 Laboratorios Liconsa, S.A. A pharmaceutical controlled release composition of losartan
JP6245983B2 (ja) 2010-08-11 2017-12-13 ドレクセル ユニバーシティ パーキンソン病におけるジスキネジアを治療するための新規ｄ３ドーパミン受容体アゴニスト
US8435993B2 (en) 2010-12-07 2013-05-07 Philadelphia Health And Education Corporation Methods of inhibiting metastasis from cancer
US8476221B2 (en) 2011-03-18 2013-07-02 Halimed Pharmaceuticals, Inc. Methods and compositions for the treatment of metabolic disorders
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
US9050335B1 (en) 2011-05-17 2015-06-09 Mallinckrodt Llc Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US20130143867A1 (en) 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
BR112014015197A8 (pt) 2011-12-21 2017-06-13 Novira Therapeutics Inc agentes antivirais de hepatite b
IN2014DN09045A (enExample) 2012-05-07 2015-05-22 Bayer Pharma AG
WO2014015157A2 (en) 2012-07-19 2014-01-23 Philadelphia Health & Education Corporation Novel sigma receptor ligands and methods of modulating cellular protein homeostasis using same
EP3158995B1 (en) 2012-08-09 2018-05-23 Dynamis Therapeutics, Inc. Meglumine for reducing high triglyceride levels
WO2014107663A2 (en) 2013-01-07 2014-07-10 The Trustees Of The University Of Pennsylvania Compositions and methods for treating cutaneous t cell lymphoma
WO2014197744A1 (en) 2013-06-05 2014-12-11 Synchroneuron, Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
ES2769893T3 (es) 2013-07-02 2020-06-29 Ecoplanet Env Llc Formulaciones de compuestos orgánicos volátiles que tienen actividad antimicrobiana
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
US20160193155A1 (en) 2013-09-02 2016-07-07 Sun Pharmaceutical Industries Limited Pulsatile-release dosage form
WO2015080943A1 (en) 2013-11-26 2015-06-04 Yale University Novel cell-penetrating compositions and methods using same
CN106029672B (zh) 2013-12-06 2019-03-29 基因泰克公司 丝氨酸/苏氨酸激酶抑制剂
CA2933464A1 (en) 2013-12-09 2015-06-18 Thomas Jefferson University Use of abc drug efflux inhibitors in combination with anti-neurodegenerative drugs in the treatment of neurodegenerative disorders
WO2015157262A1 (en) 2014-04-07 2015-10-15 Women & Infants Hospital Of Rhode Island Novel 7-Dehydrocholesterol Derivatives and Methods Using Same
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
EP3182979B1 (en) 2014-08-20 2023-12-06 Yale University Novel compositions and methods useful for treating or preventing liver diseases or disorders, and promoting weight loss
WO2016182968A1 (en) 2015-05-08 2016-11-17 Brown University Novel syringolin analogues and methods of making and using same
EP4414028A3 (en) 2015-05-19 2024-11-27 Yale University Compositions for treating pathological calcification conditions, and methods using same
US10829440B2 (en) 2015-06-12 2020-11-10 Brown University Antibacterial compounds and methods of making and using same
HK1245079A1 (zh) 2015-06-30 2018-08-24 纽拉德有限公司 新颖呼吸控制调节化合物以及其制备和使用方法
JP2018521077A (ja) * 2015-07-29 2018-08-02 タケダ ゲー・エム・ベー・ハーＴａｋｅｄａ ＧｍｂＨ 糖尿病性腎症を治療するためのｐｄｅ４阻害剤
EP3368505B1 (en) 2015-10-28 2023-02-22 Yale University Quinoline amides and methods of using same
EP3377105A4 (en) 2015-11-20 2019-04-24 Yale University COMPOSITIONS FOR THE TREATMENT OF ECTOPIC CALIBRATION DISORDERS AND METHODS THEREWITH
US9675585B1 (en) 2016-03-24 2017-06-13 Ezra Pharma Extended release pharmaceutical formulations
US9687475B1 (en) 2016-03-24 2017-06-27 Ezra Pharma Llc Extended release pharmaceutical formulations with controlled impurity levels
US20190119364A1 (en) 2016-04-29 2019-04-25 The Regents Of The University Of Colorado, A Body Corporate Compounds and compositions useful for treating metabolic syndrome, and methods using same
WO2018026764A1 (en) 2016-08-01 2018-02-08 University Of Rochester Nanoparticles for controlled release of anti-biofilm agents and methods of use
CA3032467A1 (en) 2016-08-05 2018-02-08 Yale University Compositions and methods for stroke prevention in pediatric sickle cell anemia patients
ES2896487T3 (es) 2016-09-01 2022-02-24 Mebias Discovery Llc Derivados de urea sustituidos para el tratamiento del dolor
SG11201902944TA (en) 2016-11-07 2019-05-30 Arbutus Biopharma Corp Substituted pyridinone-containing tricyclic compounds, and methods using same
WO2018136766A1 (en) 2017-01-19 2018-07-26 Temple University-Of The Commonwealth System Of Higher Education Novel bridged bicycloalkyl-substituted aminothizoles and their methods of use
MA49014A (fr) 2017-03-21 2020-02-05 Arbutus Biopharma Corp Dihydroindène-4-carboxamides substitués, leurs analogues et procédés d'utilisation correspondant
US11166953B2 (en) 2017-04-17 2021-11-09 Yale University Compounds, compositions and methods of treating or preventing acute lung injury
WO2019023621A1 (en) 2017-07-28 2019-01-31 Yale University ANTICANCER DRUGS AND METHODS OF MAKING AND USING THEM
EP3679063A4 (en) 2017-09-08 2021-06-02 The Regents of The University of Colorado, A Body Corporate COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATMENT OR PREVENTION OF HER-CONTROLLED DRUG-RESISTANT CANCER
CN111818929A (zh) 2017-11-27 2020-10-23 由卫生与公众服务部部长代表的美利坚合众国 用于治疗和/或预防牙周疾病的化合物、组合物和方法
AU2018388577B2 (en) 2017-12-18 2024-06-06 Tris Pharma, Inc. Modified release drug powder composition comprising gastro-retentive raft forming systems having trigger pulse drug release
WO2019126214A1 (en) 2017-12-18 2019-06-27 Tris Pharma, Inc. Pharmaceutical composition comprising ghb gastro-retentive raft forming systems having trigger pulse drug release
CA3085941A1 (en) 2017-12-18 2019-06-27 Tris Pharma, Inc. Ghb pharmaceutical compositions comprising a floating interpenetrating polymer network forming system
CA3097737A1 (en) 2017-12-18 2019-06-27 Tris Pharma, Inc. Pharmaceutical compositions comprising a floating interpenetrating polymer network forming system
WO2019125184A1 (en) 2017-12-19 2019-06-27 Auckland Uniservices Limited Use of biomarker in cancer therapy
TW201944989A (zh) 2018-01-24 2019-12-01 洛克斐勒大學 抗菌化合物、其組成物及使用其之方法
US11897942B2 (en) 2018-05-25 2024-02-13 Temple University—Of the Commonwealth System of Higher Education Eradication of bacterial biofilm using anti-amyloid monoclonal antibodies
JP2021525269A (ja) 2018-05-29 2021-09-24 セルシィ セラピューティクス，インコーポレーテッド 疼痛処置のための化合物、それを含む組成物及びそれを使用する方法
TWI826492B (zh) 2018-07-27 2023-12-21 加拿大商愛彼特生物製藥公司 經取代四氫環戊[c]吡咯、經取代二氫吡咯，其類似物及使用其之方法
CA3109798A1 (en) 2018-08-17 2020-02-20 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of acute lung injury
CA3113377A1 (en) 2018-10-11 2020-04-16 Sanifit Therapeutics S.A. Inositol phosphates for the treatment of ectopic calcification
WO2020081762A1 (en) 2018-10-19 2020-04-23 Temple University-Of The Commonwealth System Of Higher Education Tamper-resistant drug dosage forms and methods of making and use thereof
TW202415643A (zh) 2018-12-12 2024-04-16 加拿大商愛彼特生物製藥公司 經取代之芳基甲基脲類及雜芳基甲基脲類、其類似物及其使用方法
MX2021008966A (es) 2019-01-30 2021-11-04 Sanifit Therapeutics S A Compuestos de fosfato de inositol para su uso en el aumento de la perfusion tisular.
US20200246317A1 (en) 2019-02-01 2020-08-06 Cersci Therapeutics, Inc. Methods of treating diabetic neuropathy with a thiazoline anti-hyperalgesic agent
WO2020159565A1 (en) 2019-02-01 2020-08-06 Cersci Therapeutics, Inc. Methods of treating post-surgical pain with a thiazoline anti-hyperalgesic agent
CA3136665A1 (en) 2019-04-12 2020-10-15 Sdg, Inc. Lipid-based nanoparticles and use of same in optimized insulin dosing regimens
EP3965792A4 (en) 2019-05-09 2023-01-18 The Feinstein Institutes for Medical Research HMGB1 ANTAGONIST
JP2022538767A (ja) 2019-06-12 2022-09-06 ザ ウィスター インスティテュート アセチルＣｏＡシンテターゼ２（ＡＣＳＳ２）阻害剤およびそれを使用する方法
US11555010B2 (en) 2019-07-25 2023-01-17 Brown University Diamide antimicrobial agents
EP3818983A1 (en) 2019-11-11 2021-05-12 Sanifit Therapeutics S.A. Inositol phosphate compounds for use in treating, inhibiting the progression, or preventing cardiovascular calcification
WO2021127456A1 (en) 2019-12-19 2021-06-24 Rain Therapeutics Inc. Methods of inhibiting epidermal growth factor receptor proteins
WO2021252549A1 (en) 2020-06-09 2021-12-16 Inozyme Pharma, Inc. Soluble enpp1 or enpp3 proteins and uses thereof
CN116546984A (zh) 2020-09-28 2023-08-04 耶鲁大学 5-ht2a受体的选择性激动剂及其使用方法
EP4015494A1 (en) 2020-12-15 2022-06-22 Sanifit Therapeutics S.A. Processes for the preparation of soluble salts of inositol phosphates
EP4036097A1 (en) 2021-01-29 2022-08-03 Sanifit Therapeutics S.A. Ip4-4,6 substituted derivative compounds
TW202412815A (zh) 2022-07-29 2024-04-01 西班牙商薩尼菲特治療公司 Ip5經取代化合物
AU2023313374A1 (en) 2022-07-29 2025-02-13 Vifor (International) Ltd. Ip4-4,6 substituted derivative compounds for use in the treatment, inhibition of progression, and prevention of ectopic calcification
WO2024052895A1 (en) 2022-09-06 2024-03-14 Hadasit Medical Research Services And Development Ltd Combinations comprising psychedelics for the treatment of schizophrenia and other neuropsychiatric and neurologic disorders
JP2026513019A (ja) 2023-02-03 2026-04-22 トリス・フアルマ・インコーポレーテツド １晩１回の低ナトリウムオキシベート組成物
TW202513071A (zh) 2023-08-14 2025-04-01 以色列商琉璃藥品 (1991) 有限公司 Gal475組合物及其使用方法
WO2025162971A1 (en) 2024-01-31 2025-08-07 Sanifit Therapeutics, S.A. Substituted ip5 compounds for use in the treatment, inhibition of progression, and prevention of ectopic calcification
WO2025217096A1 (en) 2024-04-08 2025-10-16 University Of Rochester Inhibitors of leucine-rich repeat kinase 2 (lrrk2) and medical uses thereof
WO2025217094A1 (en) 2024-04-08 2025-10-16 University Of Rochester Interleukin receptor-associated kinase (irak) protac degraders and medical use thereof
WO2025217379A1 (en) 2024-04-10 2025-10-16 University Of Rochester Drug treatment for macular degeneration
WO2026050206A1 (en) 2024-08-27 2026-03-05 Ironwood Pharmaceuticals, Inc. Combinations of glp-1 and guanylate cyclase c (gc-c) receptor agonists

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5138069A (en) * 1986-07-11 1992-08-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
US5007790A (en) * 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
US5582837A (en) * 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
US5972990A (en) * 1992-04-10 1999-10-26 Brigham And Women's Hospital, Inc. Methods for reducing risk of repeat myocardial infarction and increasing survival in heart attack victims
US5266583A (en) * 1992-09-01 1993-11-30 Merck & Co., Inc. Angitotensin II antagonist
US5264447A (en) * 1992-09-01 1993-11-23 Merck & Co., Inc. Angiotensin II antagonist
US5824696A (en) * 1993-09-01 1998-10-20 Smithkline Beecham Corporation Medicaments
US5464854A (en) * 1993-11-11 1995-11-07 Depadova; Anathony S. Method of modifying ovarian hormone-regulated AT1 receptor activity as treatment of incapacitating symptom(s) of P.M.S.
AU685898B2 (en) * 1993-12-23 1998-01-29 Du Pont Merck Pharmaceutical Company, The Polymorphs of losartan and the process for the preparation of form II of losartan
CA2213404C (en) * 1995-02-28 2001-09-25 Handelman, Joseph H. Use of angiogenesis suppressors for inhibiting hair growth
US5645839A (en) * 1995-06-07 1997-07-08 Trustees Of Boston University Combined use of angiotensin inhibitors and nitric oxide stimulators to treat fibrosis
SE9502219D0 (sv) * 1995-06-19 1995-06-19 Astra Ab Novel medical use
JPH11508894A (ja) 1995-06-30 1999-08-03 メルク エンド カンパニー インコーポレーテッド Ａｃｅ阻害剤とａｉｉ拮抗薬を用いる腎疾患の治療方法
EP0868179A4 (en) 1995-12-12 2002-01-30 Merck & Co Inc NEW USE OF LOSARTAN
FR2746013B1 (fr) * 1996-03-18 1998-05-29 Sanofi Sa Utilisation de composes antiarythmiques dans la prevention de la mortalite post infarctus
JP2000513356A (ja) * 1996-06-24 2000-10-10 メルク エンド カンパニー インコーポレーテッド エナラプリルとロサルタンの組成物
US6087386A (en) * 1996-06-24 2000-07-11 Merck & Co., Inc. Composition of enalapril and losartan
US5972389A (en) * 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
ATE214388T1 (de) * 1996-10-29 2002-03-15 Merck & Co Inc Verfahren zur kristallisation von losartan
US6008221A (en) * 1996-11-06 1999-12-28 Bristol-Myers Squibb Company Method for treating Alzheimer's disease with folic acid
US5795904A (en) * 1996-12-06 1998-08-18 Merck & Co., Inc. Enhanced functional recovery of the heart by losartan treatment after an ischemic attach
US6110895A (en) * 1996-12-16 2000-08-29 University Of Southern California Method of promoting healing in skin grafts
US6201002B1 (en) * 1997-01-10 2001-03-13 Merck & Co., Inc. Method for reducing mortality with an angiotensin II antagonist
US5872984A (en) * 1997-04-01 1999-02-16 International Business Machines Corporation Uninterruptible power supply providing continuous power mainstore function for a computer system
US6191156B1 (en) * 1997-04-11 2001-02-20 The Brigham And Women's Hospital, Inc. Compositions and methods for treating bladder dysfunction
WO1998055107A1 (en) 1997-06-06 1998-12-10 Depomed, Inc. Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
ATE241341T1 (de) * 1997-09-10 2003-06-15 Takeda Chemical Industries Ltd Stabilisierte pharmazeutische zusammensetzung
US6103266A (en) * 1998-04-22 2000-08-15 Tapolsky; Gilles H. Pharmaceutical gel preparation applicable to mucosal surfaces and body tissues
AU750122C (en) * 1998-06-17 2003-02-27 Bristol-Myers Squibb Company Preventing cerebral infarction through administration of ADP-receptor antiplatelet and antihypertensive drugs in combination
YU78601A (sh) * 1999-05-05 2005-07-19 Aventis Pharma Deutschland Gmbh. 1-(p-tienilbenzil)-imidazoli kao agonisti angiotenzin-(1-7)- receptora, postupak za njihovu proizvodnju, njihova primena i farmaceutski preparati koji ih sadrže
HK1050135A1 (zh) 1999-11-02 2003-06-13 Depomed, Inc. 用於促进将药物给予胃的饭後模式药理学诱导
DE60123384T2 (de) 2000-02-04 2007-08-02 DepoMed, Inc., Menlo Park Dosierungsform des typs "hülle und kern" mit einer wirkstofffreisetzung, die sich der nullten ordnung annähert
CN1440283A (zh) * 2000-04-12 2003-09-03 诺瓦提斯公司 有机化合物的联合形式
US6488962B1 (en) * 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
US6451808B1 (en) * 2000-10-17 2002-09-17 Depomed, Inc. Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists
MXPA03011096A (es) 2001-05-29 2004-12-06 Depomed Dev Ltd Metodo para el tratamiento de la enfermedad de reflujo gastroesofagico y la saturacion acida nocturna.
US6669955B2 (en) * 2001-08-28 2003-12-30 Longwood Pharmaceutical Research, Inc. Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin

Also Published As

Publication number Publication date
WO2003035039A1 (en) 2003-05-01
JP2005508358A (ja) 2005-03-31
EP1438027A1 (en) 2004-07-21
US7413751B2 (en) 2008-08-19
US20030158244A1 (en) 2003-08-21

Similar Documents

Publication Publication Date Title
US7413751B2 (en) Methods of treatment using a gastric retained losartan dosage
US8580303B2 (en) Gastric retained gabapentin dosage form
AU2002348828A1 (en) Methods of treatment using a gastric retained gabapentin dosage
WO2007086078A2 (en) Novel pharmaceutical compositions and process of preparation thereof
JP2007532620A (ja) 両親媒性デンプンを含む医薬組成物
EP1140027A1 (en) Dosage forms comprising porous particles
EP1107741A1 (en) Orally administered controlled drug delivery system providing temporal and spatial control
JP4177227B2 (ja) 薬物の経口投与用徐放性組成物
KR20120075029A (ko) 위체류 약물 전달시스템을 이용한 경구용 방출제어형 레바미피드-함유 이층정 제제 및 그 제조방법
JP3751287B2 (ja) 小型化されたニフェジピン有核錠剤
AU2002348827A1 (en) Methods of treatment using a gastric retained losartan dosage
WO2025046633A1 (en) Extended-release formulations for cilnidipine and their manufacturing processes
CN87107534A (zh) 哌胺甲尿啶的药剂形式

Legal Events

Date Code Title Description
FZDE Dead